This volume of Pharmaceutical Biocatalysis starts with a discussion on the importance of biocatalytic synthesis approaches for a sustainable and environmentally friendly production of pharmaceuticals and active pharmaceutical ingredients. Among the enzymes discussed in detail with respect to their pharmaceutical relevance are cyclic nucleotide phosphodiesterases playing an important role in modulating signal transduction in various cell types; human DOPA decarboxylase, related to Parkinson's disease and aromatic amino acid decarboxylase deficiency; and phospholipase D enzymes as drug targets. Isocitrate dehydrogenase 1 and 2 mutations are novel therapeutic targets in acute myeloid leukemia. An additional chapter is devoted to the use of enzymes for prodrug activation in cancer therapy. The other topics include small-molecule inhibitors targeting receptor tyrosine kinases in cancer, β-Lactams and related compounds as antibacterials, non-vitamin K oral anticoagulants for the treatment of thromboembolic diseases, and the molecular mechanisms for statin pleiotropy and its clinical relevance in cardiovascular diseases. The last chapter is a review of lysosomal storage disorders with an overview of approved drugs for treating these disorders by enzyme replacement therapy.
Table of Contents
Lipase-Mediated Biocatalysis as a Greener and Sustainable Choice for Pharmaceutical Processes
Monika Sharma, Tanya Bajaj, and Rohit Sharma
Moritz Helmstädter, Manfred Schubert-Zsilavecz
Human DOPA Decarboxylase: Catalysis and Involvement in Pharmacological Treatments for Parkinson's Disease and Aromatic Amino Acid Decarboxylase Deficiency
Mariarita Bertoldi and Giada Rossignoli
Advancing Phospholipase D Enzymes as Diverse Drug Targets
Hortensia Gomes Leal and Kimberly A. Stieglitz
IDH1 and IDH2 Mutations as Novel Therapeutic Targets in Acute Myeloid Leukemia (AML): Current Perspectives
Angelo Paci et al.
Enzymes for Prodrug-Activation in Cancer Treatment and Gene Therapies
Small-Molecule Inhibitors Targeting Receptor Tyrosine Kinases in Cancer
Mohammad Hojjat-Farsangi and Reza Khamisipour
β-Lactams and Related Compounds as Antibacterials and β-Lactamase Inhibitors
Ulrike Holzgrabe and Jens Schmitz
Non-Vitamin K Oral Anticoagulants (NOACs): New Options
Molecular Mechanisms for Statin Pleiotropy and Possible Clinical Relevance in Cardiovascular Disease
J. K. Liao
Lysosomal Storage Disorders and Enzyme Replacement Therapy
Peter Grunwald studied chemistry at the Universities of Saarbrücken and Hamburg, Germany. He graduated in the field of high-frequency spectroscopy and then became a staff member of the Institute of Physical Chemistry. After receiving his PhD in physical chemistry, he founded a biotechnology research group. He was appointed professor in 2001. His research interests focus on immobilized biocatalysts, kinetics of enzymes in organic solvents, and interactions between biocatalysts and heavy metal ions. Prof. Grunwald is also interested in chemical education, including curriculum development. He has authored a textbook on biochemistry and is an editorial board member of Catalysts.